NZ794813B2 - Therapeutic solid dosage forms - Google Patents

Abstract

The present invention relates to a solid dosage form comprising two or more compounds selected from N,N-dimethyltryptamine and its deuterated analogues and pharmaceutically acceptable salts thereof.

Claims (26)

1. A solid dosage form comprising an a,a-dideutero-N,N-dimethyltryptamine compound, or a ceutically acceptable salt thereof, and one or more deuterated ues, or a pharmaceutically able salt thereof, selected from: (a) a -protio, a-deutero-N,N-dimethyltryptamine compounds; and (b) compounds of Formula I: NR2R3 R1 yH R1 N R1 (I), wherein: each R1 is independently selected from H and D; R2 is selected from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D; and the ratio of deuterium:protium in a compound of Formula I is greater than that found naturally in hydrogen.

2. The solid dosage form of claim 1, wherein each R1 is H.

3. The solid dosage form of claim 1 or claim 2, wherein both yH are D.

4. The solid dosage form of any one of claims 1 to 3, wherein both R2 and R3 are

5. The solid dosage form of any one of claims 1 to 4, comprising one or more compounds selected from Compounds 1 to 5, or a pharmaceutically acceptable salt thereof: 02_1 (GHMatters) P120480.NZ

6. The solid dosage form of any one of claims 1 to 5, further comprising N,N- dimethyltryptamine or a ceutically acceptable salt thereof.

7. The solid dosage form of any one of claims 1 to 6, comprising up to 50% by weight, based on the total solid dosage form, of the a,a-dideutero-N,N- dimethyltryptamine nd and one or more deuterated analogues, and pharmaceutically acceptable salts thereof.

8. The solid dosage form of any one of claims 1 to 7, comprising from 5% to 95% by weight of N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof.

9. The solid dosage form of any one of claims 1 to 8, comprising from 5% to 95% by weight of an a,a-dideutero-N,N-dimethyltryptamine, or a pharmaceutically able salt thereof.

10. The solid dosage form of claim 6, comprising a biologically active agent which consists essentially of N,N-dimethyltryptamine, a-protio, a-deutero-N,N- dimethyltryptamine, and a,a-dideutero-N,N-dimethyltryptamine, the solid dosage form optionally being in the form of a pharmaceutically acceptable salt, wherein the mean molecular weight of N,N-dimethyltryptamine, a-protio, ero-N,N- dimethyltryptamine and a,a-dideutero-N,N-dimethyltryptamine present in the solid dosage form is less than or equal to 190.28 grams per mole. 21402702_1 (GHMatters) P120480.NZ

11. The solid dosage form of claim 6, comprising a biologically active agent which consists essentially of methyltryptamine, a-protio, ero-N,N- yltryptamine, and a,a-dideutero-N,N-dimethyltryptamine, the solid dosage form optionally being in the form of a pharmaceutically acceptable salt, wherein the mean molecular weight of N,N-dimethyltryptamine, a-protio, a-deutero-N,N- dimethyltryptamine and a,a-dideutero-N,N-dimethyltryptamine present in the solid dosage form is greater than or equal to 188.28 grams per mole.

12. The solid dosage form of claim 10 or claim 11, in which the mean molecular weight of N,N-dimethyltryptamine, a-protio, a-deutero-N,N-dimethyltryptamine and a,a-dideutero-N,N-dimethyltryptamine present in thesolid dosage form is from 188.9 to 189.7 grams per mole.

13. The solid dosage form of any one of claims 1 to 12, wherein the deutero- N,N-dimethyltryptamine nd and one or more deuterated analogues, or a pharmaceutically acceptable salt thereof, have a purity of greater than or equal to 99% by HPLC.

14. The solid dosage form of claim 13, wherein the a,a-dideutero-N,N- dimethyltryptamine compound and one or more deuterated ues, or a pharmaceutically acceptable salt thereof, have a purity of greater than or equal to 99.9% by HPLC.

15. The solid dosage form of any one of claims 1 to 14, wherein the a,a-dideutero- N,N-dimethyltryptamine compound and one or more deuterated analoguesare in the form of a pharmaceutically acceptable salt.

16. The solid dosage form of claim 15, wherein the pharmaceutically acceptable salt is a fumarate salt.

17. The solid dosage form of any one of claims 1 to 14, comprising an N,N- dimethyltryptamine compound in the form of a se.

18. The solid dosage form of any one of claims 1 to 17, comprising a pharmaceutically acceptable excipient. 21402702_1 (GHMatters) P120480.NZ

19. The solid dosage form of any one of claims 1 to 18, which is a solid oral dosage form.

20. The solid dosage form of any one of claims 1 to 19 for use in therapy.

21. The solid dosage form of claim 20, wherein the therapy is DMT-assisted psychotherapy.

22. Use of an a,a-dideutero-N,N-dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof, and one or more deuterated analogues, or a pharmaceutically acceptable salt thereof, selected from: (a) a-protio, a-deutero-N,N-dimethyltryptamine compounds; and (b) compounds of Formula I: NR2R3 R1 yH R1 N R1 (I), wherein: each R1 is independently selected from H and D; R2 is ed from CH3 and CD3; R3 is selected from CH3 and CD3; each yH is independently selected from H and D; and the ratio of deuterium:protium in a compound of a I is greater than that found naturally in hydrogen, in the manufacture of a medicament for treating a psychiatric disorder or a neurological disorder in a patient, wherein the medicament is a solid dosage form.

23. Use of a solid dosage form as defined in any one of claims 1 to 19 in the cture of a medicament for treating a psychiatric er or a neurological disorder in a patient. 21402702_1 (GHMatters) P120480.NZ

24. The use of claim 22 or claim 23, wherein the atric or neurological disorder is selected from the group consisting of (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) a schizophrenia disorder, (iv) a schizotypal disorder, (v) an anxiety disorder, (vi) substance abuse, (vii) an avolition er, and (viii) a brain injury disorder.

25. The use of claim 24, wherein the disorder is major depressive disorder.

26. The use of claim 24, wherein the disorder is ent resistant depression. 21402702_1 (GHMatters) P120480.NZ 93) 8} 2630 H3!) 30¢an 953 I50 Eo? ommthmm mmmmxo 399 Ax“. £26”me 188 189 I90 19% 188 ESQ 396 191 MW freebase (gfmei) m, Bx} MW free-beige ) $33 33mm 188 i8? 19% 391 1... .3 memmeEm?Em 99¢ “@223 am 11 AV V 3 @3333 @3833 46 ommcmb? 5 xm 188 189 1 96 191 $535 MW ?sebase (g/msi} Mean compound concentrations (PO dose) —SPL026 (DA/IT} Maia — — SPLOZBE (D2) Make — - -SPL028VEH (D8) Make 4;.0 o (ng/mL) (oS” O mf3 o concentration 25.0 Plasma 10.0 Mean compound concentrations (PO dose) 6 {DMT} Maia ISPLOZSi (D2) Male ISPLO28ini (D8) Make (ng/mL) ow.0 o concentration .b.0 C Plasma 20.0 0.0 -- Mean [AA rations (PO dose) —SPL026 {UNIT} Maia — — SPLOZBE (D2) Mam - - -SPL028VEH (D8) Make Mean lAA concentrations (PO dose) 6 (DMD Maia ISPLOZBE (D2) Make ISPLOZSVEH (D8) Make 0.0 [Egg-r E T T T Qxe’bogg $30 (9&0 NQ§9 {96$ “9&0 DEOKQS 656$ (196$ NQ>Q§9